A carregar...
Targeting secondary immune responses to cetuximab: CD137 and the outside story
Cetuximab is a murine-human chimeric IgG1 mAb directed against the EGFR that is approved for use in patients with colorectal and head and neck carcinomas. While some patients benefit greatly from cetuximab, many do not; therefore, strategies to increase the efficacy of this drug are of great clinica...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4089450/ https://ncbi.nlm.nih.gov/pubmed/24837438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI76264 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|